Clinical Trial Update: Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and immunogenicity of the 20-valent pneumococcal conjugate vaccine (20vPnC) in toddlers with two prior doses of Prevnar 13. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 20vPnC (20-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-09-19